Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-001978 Act: 34 Size: 3 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-001945 Act: 34 Size: 130 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-001937 Act: 34 Size: 139 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-001536 Act: 34 Size: 255 KB 网页链接
$Sol-gel(SLGL)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-22-001534 Act: 33 Size: 604 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-001519 Act: 34 Size: 334 KB 网页链接
$Sol-gel(SLGL)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-22-000967 Act: 33 Size: 1 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-001461 Act: 34 Size: 136 KB 网页链接
$Sol-gel(SLGL)$ F-3 Registration statement by foreign private issuers Accession Number: 0001178913-22-001457 Act: 33 Size: 566 KB 网页链接
$Sol-gel(SLGL)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-22-001452 Act: 34 Size: 7 MB 网页链接